There was a flurry of activity on the Australian cannabusiness scene towards the end of last week. Here’s some of what happened.
Zelda Therapeutics (ASX:ZLD)
Zelda announced it had achieved full enrolment in its medicinal cannabis clinical trial for insomnia. The study involves 24 patients who are being treated with either Zelda Therapeutics’ insomnia formulation or a placebo. The trial is being led by the University of Western Australia (UWA) Centre for Sleep Science (CSS). More here.
Cann Group (ASX:CAN)
Cann Group Limited announced the company is supplying its full range of imported medicinal cannabis to approved Special Access Scheme (SAS) patients via Symbion Pty Ltd, which supplies more than 4,000 retail pharmacies and 1,300 hospitals across Australia. The company also said it expects to launch the first of its locally sourced and manufactured formulations in the first quarter of next year. Additionally, Cann Group stated it has received its first high-THC oil shipment from Canadian partner Aurora Cannabis. More here.
Bod Australia (ASX:BDA)
Bod Australia Limited said on Friday the company will be participating in Europe’s largest medicinal cannabis project, which will study the effects of cannabis on thousands of patients with various chronic conditions including Multiple Sclerosis, PTSD and Tourette’s Syndrome.
It’s expected 20,000 patients will be enrolled in the program, dubbed Project Twenty21, and Bod will be one of five companies supplying products. In Bod’s case, it will be providing its MediCabilis cannabidiol formulation. Each 1mL of Medicabilis contains 50mg CBD (as CBD and CBDA). More from Bod here and more on Project Twenty21 here.
ECS Botanics (ASX:ECS)
ECS Botanics Holdings Ltd says its 250ml hemp oil product will soon be appearing in 850 Woolworths stores in Australia and the company expects to dispatch the first order in January next year. The distribution will occur via Just Foods Australia Pty Ltd (JFA). ECS noted total revenue from the arrangement is currently uncertain and no minimum volumes have been guaranteed. More here.
Cronos Australia (ASX:CAU)
Cronos Australia Limited was admitted to the Official List of the Australian Stock Exchange (ASX) last Thursday. Cronos Australia was established as a joint venture between Canada’s Cronos Group Inc (NASDAQ:CRON, TSX:CRON) and Melbourne-based private equity firm NewSouthern Capital. The company holds various Australian medical cannabis licences; including cultivation, research, manufacture, import and export.
In other Australian cannabusiness news we covered late last week, Canada-headquartered MPX International Corporation announced its wholly-owned Australian subsidiary MPX Australia Pty Ltd has been awarded a Cannabis Manufacture Licence by the nation’s Office of Drug Control.